The Concept Genome-scale metabolic models (GEMs) computationally represent the entire metabolic network of a cell. This study applied a patient-specific modeling approach to HCC, creating individualized metabolic models from tumor proteomics data to predict which metabolic enzymes could be targeted by drugs without harming normal cells.
Why Metabolism Cancer cells rewire their metabolism to support rapid proliferation. These altered metabolic dependencies create vulnerabilities not present in normal tissue. By modeling each patient's unique metabolic state, the approach identifies antimetabolites - enzyme inhibitors that kill cancer cells selectively.
Key Outcome Using personalized GEMs derived from 6 HCC patients and a comprehensive metabolic database, the team identified 147 antimetabolite candidates. Of these, 101 were predicted to be effective across all 6 patient models, and the top prediction involving L-carnitine metabolism was experimentally validated using perhexiline.
HMR 2.0 Database The Human Metabolic Reaction database version 2.0 served as the foundation, containing 8,181 reactions, 6,007 metabolites, and 3,765 genes organized across cellular compartments. This comprehensive resource was the template from which patient-specific models were derived.
tINIT Algorithm The task-driven Integrative Network Inference for Tissues (tINIT) algorithm reconstructed cell-type-specific GEMs by integrating protein expression data with the HMR 2.0 template. Reactions were included or excluded based on whether the proteins catalyzing them were expressed, subject to 56 predefined metabolic tasks that any viable cell must perform.
Proteomics Input Immunohistochemistry data from 27 HCC patient tumor biopsies provided the protein expression profiles. For 6 patients with matched non-tumor liver tissue available, paired tumor and normal GEMs were generated, enabling direct comparison of metabolic differences between cancer and adjacent healthy liver.
Model Size The 6 paired HCC GEMs contained between 4,690 and 4,967 reactions, reflecting the metabolic complexity captured by the tINIT approach. Models were consistent with known liver-specific metabolic functions including urea cycle, gluconeogenesis, and lipid metabolism.
Metabolic Task Compliance All 6 personalized models satisfied all 56 predefined metabolic tasks, confirming that the reconstructed models represent metabolically viable cell states rather than artifacts of the algorithm.
Inter-Patient Variability Despite sharing common metabolic features, the 6 patient models differed in which reactions were active, reflecting the heterogeneity of HCC at the metabolic level. This variability justified the personalized approach - a single generic HCC model would miss patient-specific vulnerabilities that only appear in individual tumor models.
Screening Strategy For each patient model, in silico knockouts of individual enzymes were simulated, testing whether inhibiting a given reaction would block tumor cell growth while sparing the 83 reference GEMs of healthy human cell types. Candidates that killed tumor but not normal cells were called antimetabolites.
Pan-HCC Targets 101 antimetabolites were effective in all 6 patient models simultaneously, representing universal HCC vulnerabilities with broad therapeutic applicability. Of these 101, 22 are already in clinical use as anticancer agents, providing retrospective validation of the approach.
Patient-Specific Targets An additional 46 antimetabolites were predicted to be effective in only a subset of patients, highlighting metabolic heterogeneity in HCC and the potential for personalized treatment selection. Cholesterol biosynthesis was the pathway with the highest density of predicted antimetabolite targets, with 30 metabolites identified in this pathway alone.
The Predicted Target The model predicted that inhibiting CPT1 (carnitine palmitoyltransferase 1), the rate-limiting enzyme in long-chain fatty acid transport into mitochondria for beta-oxidation, would selectively kill HCC cells. This pathway requires L-carnitine as an essential cofactor.
Perhexiline as a CPT1 Inhibitor Perhexiline, a CPT1 inhibitor originally developed as an antianginal drug, was used to test this prediction experimentally. At 8 and 20 micromolar concentrations, perhexiline significantly reduced HepG2 HCC cell viability, demonstrating that the model's prediction translated to biological activity.
Comparison to Sorafenib The magnitude of viability reduction observed with perhexiline at these concentrations was comparable to sorafenib, the standard-of-care systemic therapy for advanced HCC. This positions CPT1 inhibition as a potentially clinically relevant strategy and validates the modeling approach as capable of identifying genuinely effective drug targets.
Personalization Over Generic Models A key advantage of this approach is the reduction in false positives relative to generic cancer models. By modeling each patient individually and filtering against 83 healthy cell-type GEMs, the pipeline predicts only drugs that are both effective for a specific tumor and safe for normal tissue - a level of specificity not achievable with population-averaged models.
Drug Repurposing Opportunity Of the 101 pan-HCC antimetabolites, 22 are already FDA-approved anticancer agents, providing immediate repurposing candidates that could be tested in HCC without full de novo drug development. An additional set target metabolic pathways where known inhibitors exist, reducing the time-to-clinic.
Proteomics-to-Treatment Pipeline The workflow - biopsy, immunohistochemistry, model reconstruction, in silico screening, and treatment selection - is in principle executable within a clinically feasible timeframe. IHC is already routinely performed on tumor specimens, making the data acquisition step relatively straightforward for clinical implementation.
Whole-Body Integration Current models represent isolated tumor cells. Integrating whole-body pharmacokinetic and pharmacodynamic (PK/PD) models would allow predictions of drug exposure at the tumor site and systemic toxicity, substantially improving the clinical translatability of model-derived drug predictions.
Broader Omics Integration The current pipeline uses proteomics as input. Incorporating transcriptomics, metabolomics, and flux measurements would provide richer constraints on model behavior. Integration of genomic mutation data (such as IDH1/2 mutations known to affect metabolism) could further individualize predictions.
Expansion to Other Cancer Types The framework is not HCC-specific. The same tINIT-based approach could be applied to any cancer type for which tumor proteomics data and appropriate reference healthy cell-type GEMs can be assembled, potentially making personalized metabolic drug discovery broadly applicable across oncology.